切换到PegIFNα-2b导致HBsAg水平低下的患者HBsAg损失和NA受抑制

StephenW

Sci Rep. 2017 Oct 17;7(1):13383. doi: 10.1038/s41598-017-13747-9.
Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.Huang J1, Zhang K2, Chen W1, Liao J1, Luo X1, Chen R3.
Author information
1Department of Infectious Diseases, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China.2Department of Infectious Diseases, The 3rd Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.3Department of Infectious Diseases, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China. [email protected].

AbstractPatients with low hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA suppression by nucleos(t)ide analogues (NAs) achieve high rate of HBsAg loss through switching to PegIFNα in pre-registration study. The aim of this study was to achieve higher rate of HBsAg loss through extended PegIFN treatment. 98 patients with HBsAg < 2,000 IU/ml and HBV DNA < 20 IU/ml were randomized to receive PegIFNα-2b or continuing NA therapy for 60 weeks. At the end of treatment (EOT) and end of follow-up (EOF), only patients who switched to PegIFNα-2b achieved HBsAg loss (32.6%) and HBsAg seroconversion (27.9% and 25.6%). Patients who switched to PegIFNα-2b also achieved higher HBeAg seroconversion rates (65.1%) and HBeAg loss (81.4% and 90.7%) than those who continued NAs treatment. On-treatment HBsAg declines predicted the responses at EOT, and HBsAg declines at post-baseline times predicted the responses at EOF. The rates of responses were not increased through extended PegIFNα treatment. For patients with low HBsAg and HBV suppression with NAs, switching to PegIFNα-2b significantly increased the rates of HBsAg loss and HBsAg seroconversion. HBsAg decline can predict the response of switching to PegIFNα-2b following from NAs.


PMID:29042662DOI:10.1038/s41598-017-13747-9

StephenW

Sci Rep。2017 Oct 17; 7（1）：13383。 doi：10.1038 / s41598-017-13747-9。
切换到PegIFNα-2b导致HBsAg水平低下的患者HBsAg损失和NA受抑制的HBV DNA。
黄杰1，张K2 2，陈W1 1，廖杰1，罗X1，陈R3。
作者信息

1
    广东省广州总医院传染病科，广东省广州市。
2
    中山大学中山大学附属第三医院传染病科。
3
    广东省广州总医院传染病科，广东省广州市。 [email protected]。

抽象

乙型肝炎表面抗原（HBsAg）水平和乙型肝炎病毒（HBV）DNA抑制的患者通过在注册前研究中切换到PegIFNα，可以通过切换到PegIFNα来实现高度的HBsAg损失。本研究的目的是通过延长PegIFN治疗实现更高的HBsAg损失率。将98例HBsAg <2,000 IU / ml和HBV DNA <20 IU / ml的患者随机分为接受PegIFNα-2b或持续NA治疗60周。治疗结束时（EOT）和随访结束（EOF），只有切换到PegIFNα-2b的患者达到HBsAg损失（32.6％）和HBsAg血清学转换（27.9％和25.6％）。转而使用PegIFNα-2b的患者与持续NAs治疗相比，HBeAg血清学转换率（65.1％）和HBeAg损失（81.4％，90.7％）也较高。治疗HBsAg下降预测EOT的反应，HBsAg在基线后时间下降预测EOF的反应。通过延长的PegIFNα治疗，反应率没有增加。对于HBsAg低和HBV抑制的患者，切换到PegIFNα-2b可显着增加HBsAg损失和HBsAg血清转换的发生率。 HBsAg下降可以预测从NAs之后切换到PegIFNα-2b的反应。

结论：
    29042662
DOI：
    10.1038 / s41598-017-13747-9

StephenW

https://www.nature.com/articles/s41598-017-13747-9

antiHBVren

一句话：
假如是HBsAg <2,000 IU / ml和HBV DNA <20 IU / ml的患者，并且在NAs的作用下HBsAg 在缓慢下降，换用/加用 PegIFNα-2b 后，可以实现短期上岸；